Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

luspatercept-aamt

View Patient Information
A soluble, recombinant fusion protein composed of a modified form of the extracellular domain of human activin receptor type IIb (ActRIIb) and linked to the human IgG1 Fc domain, with red blood cell stimulating activity. Upon subcutaneous administration, luspatercept-aamt inhibits several ligands in the transforming growth factor (TGF)-beta superfamily. This prevents activation of a variety of TGF-beta superfamily members involved in late stage erythropoiesis and results in an increased differentiation and proliferation of erythroid progenitors. Luspatercept-aamt acts at a different, later stage than erythropoietin. This agent ultimately enhances red blood cell production and prevents anemia.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:luspatercept
US brand name:Reblozyl
Code name:ACE-536
Chemical structure:(79-L-aspartic acid(L>D))human activin receptor type-2B (ACTR-IIB, EC=2.7.11.30) precursor-(25-131)-peptide (extracellular domain fragment) fusion protein with triglycyl-human immunoglobulin heavy constant gamma 1 Fc fragment-(8-232)-peptide dimer (114-114':117-117')-bisdisulfide
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search